Research Paper Volume 11, Issue 24 pp 12315—12327

β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson’s rats

Figure 3. AAV β-arrestin2 overexpression and LID groups respectively followed by intraperitoneal injection of D1R agonist (SKF38393) or saline. Rats were rated for AIMs on days 1, 3, 5, 7, 9, 11 and 13 after the injection of SKF38393. Collecting the striatums of the following four groups to prepare tissue homogenate for WB: LID, LID plus β-arrestin2-/-, LID plus SCH23390, and LID plus β-arrestin2-/- plus SCH23390. (A) Total AIM scores; (B) axial AIM score; (C) limb limb; (D) orolingual AIM score (n = 4 for each group, total 4*4=16); (E) The protein level of D1R, phosphor-ERK1/2, phosphor-DARPP32 and FosB by WB. Data are displayed as mean ± standard error of mean; * P<0.05 vs LID + βArr+/+ + SKF38393 group (n = 4 for each group, Kruskal Wallis followed by Dunn’s test for multiple comparisons in AIM scores, ANOVA followed by LSD post-hoc comparisons in proteins detection).